Abstract
Recent research has linked early life exposure to selective serotonin reuptake inhibitor medications (SSRls) to modifications of social behaviors in children. Serotonin is a key regulator of neurodevelopment, social behaviors and mental health, and with the growing use of SSRIs to treat maternal affective disorders during the perinatal period, questions have been raised about the benefits and risks of perinatal SSRI exposure on the developing child. This review will highlight how perinatal SSRIs affect maternal care and neurodevelopmental outcomes related to social affiliative behaviors in offspring; such as play behaviors, social interactions, reproductive behaviors, and maternal care of the next generation. We will also review how early life exposure to SSRIs can alter related neurobiology, and the epigenome. Both clinical research and findings from animal models will be discussed. Understanding the impact of perinatal SSRIs on neurobehavioral outcomes will improve the health and well-being of subsequent generations.
Original language | English |
---|---|
Pages (from-to) | 102-116 |
Number of pages | 15 |
Journal | Neuroscience and Biobehavioral Reviews |
Volume | 85 |
DOIs | |
Publication status | Published - 1 Feb 2018 |
Event | Meeting of the International-Behavioral-Neuroscience-Society (IBNS) - Budapest, HUNGARY, Budapest Duration: 1 Feb 2018 → … |
Keywords
- Maternal care
- Development
- Offspring
- Perinatal depression
- SSRI
- Pregnancy
- Stress
- Play behavior
- Social interaction
- Reproductive behavior
- Antidepressant
- Sex differences
- Serotonin
- Maternal stress
- Maternal anxiety
- NEONATAL FLUOXETINE EXPOSURE
- AUTISM SPECTRUM DISORDER
- MOTHER-INFANT INTERACTIONS
- PRENATAL ANTIDEPRESSANT EXPOSURE
- DETERMINES MATERNAL-BEHAVIOR
- GONADAL HORMONE MODULATION
- DEPRESSION-LIKE BEHAVIOR
- PITUITARY-ADRENAL AXIS
- ANXIETY-LIKE BEHAVIOR
- EARLY-LIFE ADVERSITY